Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke
Phase 4
Completed
- Conditions
- Cardiovascular Disease
- Registration Number
- NCT00147602
- Lead Sponsor
- Pfizer
- Brief Summary
To determine whether Lipitor reduces stroke, compared to placebo in patients who have had a previous stroke or transient ischemic attack.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 4732
Inclusion Criteria
- Previous stroke or TIA
Exclusion Criteria
- coronary heart disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Time to occurrence of fatal or non-fatal stroke
- Secondary Outcome Measures
Name Time Method Time to occurrence of a cerebrovascular event, defined as fatal or nonfatal stroke or TIA. Time to occurrence of an acute coronary event, consisting of cardiac death, nonfatal myocardial infarction, resuscitated cardiac arrest or unstable angina.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of atorvastatin reduce cerebrovascular events in post-stroke patients?
How does atorvastatin compare to other statins in preventing secondary strokes in TIA/stroke survivors?
Which biomarkers correlate with atorvastatin efficacy in secondary stroke prevention trials?
What are the long-term adverse event profiles of high-dose atorvastatin in post-stroke populations?
How do combination therapies with atorvastatin and antiplatelet agents impact stroke recurrence rates compared to monotherapy?
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇻🇪Caracas, Venezuela
Pfizer Investigational Site🇻🇪Caracas, Venezuela